Published: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 701 to 750 of 872

Sort by

Guidance programme: Technology appraisal guidanceRemove Guidance programme: Technology appraisal guidance filter

Published guidance, NICE advice and quality standards
Title	Reference number	Published	Last updated
Edoxaban for treating and for preventing deep vein thrombosis and pulmonary embolism	TA354	26 August 2015	26 August 2015
Naloxegol for treating opioid‑induced constipation	TA345	22 July 2015	22 July 2015
Aflibercept for treating diabetic macular oedema	TA346	22 July 2015	22 July 2015
Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer	TA347	22 July 2015	22 July 2015
Everolimus for preventing organ rejection in liver transplantation	TA348	22 July 2015	22 July 2015
Secukinumab for treating moderate to severe plaque psoriasis	TA350	22 July 2015	22 July 2015
Cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy (terminated appraisal)	TA351	22 July 2015	22 July 2015
Omalizumab for previously treated chronic spontaneous urticaria	TA339	8 June 2015	8 June 2015
Vedolizumab for treating moderately to severely active ulcerative colitis	TA342	5 June 2015	5 June 2015
Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism	TA341	4 June 2015	4 June 2015
Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia	TA343	2 June 2015	2 June 2015
Rivaroxaban for preventing adverse outcomes after acute management of acute coronary syndrome	TA335	25 March 2015	25 March 2015
Empagliflozin in combination therapy for treating type 2 diabetes	TA336	25 March 2015	25 March 2015
Rifaximin for preventing episodes of overt hepatic encephalopathy	TA337	25 March 2015	25 March 2015
Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy	TA329	25 February 2015	25 February 2015
Sofosbuvir for treating chronic hepatitis C	TA330	25 February 2015	25 February 2015
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment	TA333	25 February 2015	25 February 2015
Regorafenib for metastatic colorectal cancer after treatment for metastatic disease (terminated appraisal)	TA334	25 February 2015	25 February 2015
Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma	TA269	12 December 2012	1 January 2015
Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism	TA327	17 December 2014	17 December 2014
Erythropoiesis‑stimulating agents (epoetin and darbepoetin) for treating anaemia in people with cancer having chemotherapy	TA323	26 November 2014	26 November 2014
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome without atrioventricular block	TA324	26 November 2014	26 November 2014
Nalmefene for reducing alcohol consumption in people with alcohol dependence	TA325	26 November 2014	26 November 2014
Imatinib for the adjuvant treatment of gastrointestinal stromal tumours	TA326	26 November 2014	26 November 2014
Dual‑chamber pacemakers for symptomatic bradycardia due to sick sinus syndrome and/or atrioventricular block	TA88	23 February 2005	1 November 2014
Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma	TA321	22 October 2014	22 October 2014
Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis	TA320	27 August 2014	27 August 2014
Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen	TA316	23 July 2014	23 July 2014
Prasugrel with percutaneous coronary intervention for treating acute coronary syndromes	TA317	23 July 2014	23 July 2014
Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma	TA319	23 July 2014	23 July 2014
Implantable cardioverter defibrillators and cardiac resynchronisation therapy for arrhythmias and heart failure	TA314	25 June 2014	25 June 2014
Canagliflozin in combination therapy for treating type 2 diabetes	TA315	25 June 2014	25 June 2014
Teriflunomide for treating relapsing–remitting multiple sclerosis	TA303	22 January 2014	1 June 2014
Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer	TA310	23 April 2014	23 April 2014
Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation	TA311	23 April 2014	23 April 2014
Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis	TA308	26 March 2014	26 March 2014
Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy	TA307	25 March 2014	25 March 2014
Total hip replacement and resurfacing arthroplasty for end-stage arthritis of the hip	TA304	26 February 2014	26 February 2014
Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion	TA305	26 February 2014	26 February 2014
Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin's B‑cell lymphoma	TA306	26 February 2014	26 February 2014
Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C	TA106	23 August 2006	27 November 2013
Canakinumab for treating systemic juvenile idiopathic arthritis (terminated appraisal)	TA302	27 November 2013	27 November 2013
Peginterferon alfa and ribavirin for treating chronic hepatitis C in children and young people	TA300	27 November 2013	27 November 2013
Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C	TA75	28 January 2004	27 November 2013
Pazopanib for the first-line treatment of advanced renal cell carcinoma	TA215	23 February 2011	1 August 2013
Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder	TA292	24 July 2013	24 July 2013
Aflibercept solution for injection for treating wet age‑related macular degeneration	TA294	24 July 2013	24 July 2013
Rivaroxaban for treating pulmonary embolism and preventing recurrent venous thromboembolism	TA287	26 June 2013	26 June 2013
Mirabegron for treating symptoms of overactive bladder	TA290	26 June 2013	26 June 2013
Bevacizumab in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer	TA284	22 May 2013	22 May 2013

Results per page

10
25
50
All